Company: ENTXW
Filing Date: 2025-05-14
Form Type: PRE 14A
Source: 0001178913-25-001794
Chunk: 43

Company: Entera Bio Ltd.
Filing Date: 2025-05-14
Form: PRE 14A
Chunk 43
---
     |           |   531 |
| Chief Operating Officer              |     | 2023 |     |            | 245 |     |           | - |     |          | 163 |     |              |   - |     |              | 31 |     |           |   459 |
| Dana Yaacov-Garbeli                  |     | 2024 |     |            | 226 |     |           | - |     |          | 158 |     |              |  54 |     |              |  - |     |           |   438 |
| Chief Finance Officer                |     | 2023 |     |            | 193 |     |           |   |     |          | 118 |     |              |   - |     |              |  - |     |           |   311 |

| (1) | Reflects the associated annual expense recorded in our financial statements based on the grant date fair value of the share-based compensation granted in exchange for the directors’ and officers’ services computed in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation - Stock Compensation (“ASC Topic 718”). The assumptions used in calculating the amounts are discussed in Note 6 to the Company’s audited financial statements for the year ended December 31, 2024 included in the 2024 Annual Report. The fair value amount is recognized as an expense over the course of the vesting period of the options (subject to any applicable accounting adjustments during that period). |

| (2) | Reflects the associate annual expenses for RSUs granted in place of annual bonus in cash recorded in our financial statements based on the fair value of the share-based compensation grant date market computed in accordance with ASC Topic 718. The fair value amount is recognized as an expense over the course of the vesting period of the RSUs in the Company’s audited financial statements for the year ended December 31, 2024 included in the 2024 Annual Report. |

26 Outstanding Equity Awards at Fiscal Year End The following table sets forth the outstanding equity awards at December 31, 2024 for our Named Executive Officers.

|                                      |     | Number of SecuritiesUnderlyingUnexercised Options |         |     |               |         |     | Option     
 Expiration |
| Name                                 |     | Exercisable                                       |         |     | Unexercisable |         |     | Date       |
| Miranda